Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Neurology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles